[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


2. Tachu B, Pillai S, Lucius R, Pogonka T: Essential role of chitinase in the development of the filarial nematode Acanthocheilonema viteae. Infect Immun; 2008 Jan;76(1):221-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Northern blot experiments and rapid amplification of cDNA ends-PCR with adult worms and larval stages showed that only one gene is expressed, with high variation in transcript levels, as determined by real-time PCR.
  • Chitinase transcript levels were lowest in the late male stage 4 larva (L4) and peaked in the stage 3 larva (L3), which was corroborated by Western blotting.
  • RNA interference (RNAi) experiments showed that treatment of L3 and adult female worms with double-stranded RNA of chitinase inhibited molting of L3 worms and hatching of microfilariae.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biochem Parasitol. 1996 Jan;75(2):207-19 [8992319.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1441-7 [8576136.001]
  • [Cites] Exp Parasitol. 1999 Oct;93(2):73-81 [10502469.001]
  • [Cites] Parasitology. 2004 Dec;129(Pt 6):655-61 [15648688.001]
  • [Cites] Dev Biol. 2005 Sep 15;285(2):330-9 [16098962.001]
  • [Cites] Genome Res. 1999 Nov;9(11):1026-39 [10568743.001]
  • [Cites] Parasitol Today. 1999 Mar;15(3):123 [10322327.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17929-32 [10770921.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 15;29(12):2581-93 [11410667.001]
  • [Cites] Mol Genet Genomics. 2001 Sep;266(1):28-34 [11589574.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42557-64 [11535590.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Insect Biochem Mol Biol. 2003 Jun;33(6):631-48 [12770581.001]
  • [Cites] Mol Biochem Parasitol. 2003 Jun;129(1):41-51 [12798505.001]
  • [Cites] Eur J Biochem. 2004 Jan;271(2):253-62 [14717693.001]
  • [Cites] Parasitology. 1980 Oct;81(2):447-63 [7003502.001]
  • [Cites] Mol Biochem Parasitol. 1985 Oct;17(1):93-104 [3932852.001]
  • [Cites] Mol Biochem Parasitol. 1987 Oct;25(3):267-72 [3696175.001]
  • [Cites] Methods Enzymol. 1990;183:252-78 [2314278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1548-52 [1542646.001]
  • [Cites] Comp Biochem Physiol B. 1992 Nov;103(3):681-6 [1458842.001]
  • [Cites] Mol Biochem Parasitol. 1993 Apr;58(2):317-23 [8479456.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18567-72 [8103047.001]
  • [Cites] Infect Immun. 1994 May;62(5):1901-8 [8168956.001]
  • [Cites] Appl Parasitol. 1995 Feb;36(1):22-33 [7780447.001]
  • [Cites] Mol Biochem Parasitol. 1996 Oct 1;80(2):149-58 [8892292.001]
  • (PMID = 17938220.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF052872/ EF052873/ U14638
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Helminth Proteins; EC 3.2.1.14 / Chitinase
  • [Other-IDs] NLM/ PMC2223640
  •  go-up   go-down


3. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med; 2006 Jun 8;354(23):2431-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of Burkitt's lymphoma.
  • BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments.
  • We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma.
  • Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes.
  • Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods.
  • Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
  • CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / genetics. Gene Expression. Gene Expression Profiling. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bayes Theorem. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Genes, MHC Class I. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. NF-kappa B / genetics. Oligonucleotide Array Sequence Analysis. Survival Analysis. Transcription, Genetic. Translocation, Genetic


Advertisement
4. Murthy PK, Dixit S, Gaur RL, Kumar R, Sahoo MK, Shakya N, Joseph SK, Palne S, Gupta S: Influence of Brugia malayi life stages and BmAFII fraction on experimental Leishmania donovani infection in hamsters. Acta Trop; 2008 May;106(2):81-9
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The influence of live Brugia malayi parasites and a Sephadex G-200 fraction of the adult parasite extract (BmAFII) on the progression of Leishmania donovani infection was studied.
  • Inbred hamsters were first infected with B. malayi infective 3rd stage larvae (L3), adult worms or microfilariae (mf), and then with L. donovani amastigotes (Ld), or vice versa or received both the infections simultaneously; a group of animals were first immunized with BmAFII and then infected with Ld. L. donovani parasite burden was determined between 17 and 19 days post amastigote challenge (p.a.c.) and, in case of immunized animals, between 32 and 35 days p.a.c also.
  • Leishmanial parasite burden was significantly reduced in animals exposed to filarial L3 before amastigote inoculation and in animals given filarial adult worms after or together with amastigotes.
  • The findings show, for the first time, that B. malayi L3/adult worms or immunization with BmAFII inhibits progression of L. donovani infection in hamsters and this is associated with upregulation of NO and lymphocyte proliferative responses indicating that Th1 response might be responsible for this.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329620.001).
  • [ISSN] 0001-706X
  • [Journal-full-title] Acta tropica
  • [ISO-abbreviation] Acta Trop.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Helminth; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


5. Giacomin PR, Wang H, Gordon DL, Botto M, Dent LA: Loss of complement activation and leukocyte adherence as Nippostrongylus brasiliensis develops within the murine host. Infect Immun; 2005 Nov;73(11):7442-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Substantive deposition of C3 and adherence of eosinophil-rich leukocytes were seen with infective-stage (L3) but not with lung-stage (L4) larvae.
  • Adult intestinal worms had low to intermediate levels of both C3 and leukocyte binding.
  • For L3 and adult worms, complement deposition was principally dependent on the alternative pathway.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Trop Med Hyg. 1980 Sep;29(5):842-8 [7435788.001]
  • [Cites] Aust J Exp Biol Med Sci. 1979 Oct;57(5):459-66 [548018.001]
  • [Cites] Parasite Immunol. 1983 Mar;5(2):183-94 [6601790.001]
  • [Cites] Adv Parasitol. 1984;23:143-235 [6397977.001]
  • [Cites] Acta Trop. 1985 Jun;42(2):157-63 [2862778.001]
  • [Cites] Exp Parasitol. 1986 Feb;61(1):86-94 [3943595.001]
  • [Cites] Science. 1986 Oct 31;234(4776):603-7 [3094145.001]
  • [Cites] Parasite Immunol. 1987 Jan;9(1):133-43 [3550601.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1987 Mar;18(1):66-72 [3660070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] Exp Parasitol. 1988 Apr;65(2):157-67 [2450771.001]
  • [Cites] J Immunol. 1988 Jul 1;141(1):273-8 [3132503.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1987;82 Suppl 4:213-6 [2474124.001]
  • [Cites] Eur J Immunol. 1990 Jan;20(1):221-7 [2307175.001]
  • [Cites] J Parasitol. 1990 Jun;76(3):377-82 [2352068.001]
  • [Cites] Curr Opin Immunol. 2000 Feb;12(1):44-51 [10679403.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4544-51 [11035095.001]
  • [Cites] Exp Parasitol. 2000 Aug;95(4):231-9 [11038306.001]
  • [Cites] Parasite Immunol. 2001 Jan;23(1):27-37 [11136475.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1786-93 [12085326.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5604-11 [12228288.001]
  • [Cites] J Helminthol. 2003 Jun;77(2):119-24 [12756065.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6402-10 [14573661.001]
  • [Cites] Immunity. 2004 Mar;20(3):267-77 [15030771.001]
  • [Cites] Parasite Immunol. 2003 Nov-Dec;25(11-12):545-52 [15053775.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):201-10 [15251425.001]
  • [Cites] Infect Immun. 2004 Nov;72(11):6633-41 [15501796.001]
  • [Cites] J Cell Physiol. 1977 Mar;90(3):535-52 [856837.001]
  • [Cites] J Immunol. 1979 Oct;123(4):1551-7 [113459.001]
  • [Cites] Ann Trop Med Parasitol. 1990 Apr;84(2):185-91 [2200361.001]
  • [Cites] Int J Parasitol. 1990 Aug;20(5):587-93 [2228422.001]
  • [Cites] J Exp Med. 1990 Nov 1;172(5):1425-31 [2230651.001]
  • [Cites] Parasite Immunol. 1991 Jan;13(1):13-22 [2014134.001]
  • [Cites] Exp Parasitol. 1992 May;74(3):290-9 [1582481.001]
  • [Cites] Parasitology. 1993 Jun;106 ( Pt 5):463-9 [8341582.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4 [8524789.001]
  • [Cites] Parasitol Res. 1995;81(5):398-402 [7501639.001]
  • [Cites] J Immunol. 1996 Jul 15;157(2):549-56 [8752901.001]
  • [Cites] Parasite Immunol. 1995 Nov;17(11):555-9 [8817601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8720-5 [9238044.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:45-50 [9363925.001]
  • [Cites] Parasite Immunol. 1998 Feb;20(2):93-103 [9572052.001]
  • [Cites] Nat Genet. 1998 May;19(1):56-9 [9590289.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):989-93 [9916122.001]
  • [Cites] Infect Immun. 1999 Oct;67(10):5315-23 [10496911.001]
  • [Cites] J Immunol. 1980 Jun;124(6):2886-91 [6989909.001]
  • [Cites] J Pathol. 1981 Feb;133(2):161-75 [7205445.001]
  • (PMID = 16239545.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 80295-33-6 / Complement C1q; EC 3.4.21.47 / Complement Factor B
  • [Other-IDs] NLM/ PMC1273855
  •  go-up   go-down


6. Simcock DC, Brown S, Neale JD, Przemeck SM, Simpson HV: L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake. Exp Parasitol; 2006 Jan;112(1):1-7
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake.
  • Oxygen consumption by L3 and adult Ostertagia (Teladorsagia) circumcincta was examined in vitro to determine whether oxygen can be utilised in metabolism.
  • Rates of consumption (in nmol O2/h/1000 worms) were 13+/-1 in sheathed L3, 34+/-6 in ex-sheathed L3, and 1944+/-495 in adult worms.
  • Consumption was inhibited 95% by cyanide in L3 and 74% in adults.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM CYANIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198342.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose; MQD255M2ZO / Potassium Cyanide; S88TT14065 / Oxygen
  •  go-up   go-down


7. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


8. Díaz-Camacho SP, Delgado-Vargas F, Willms K, de la Cruz-Otero Mdel C, Guadalupe Rendón-Maldonado J, Robert L, Antuna S, Nawa Y: Intrahepatic growth and maturation of Gnathostoma turgidum in the natural definitive opossum host, Didelphis virginiana. Parasitol Int; 2010 Sep;59(3):338-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results show that tiny (<3mm in length) third stage larvae (L3) appeared in the liver of opossums around November and December.
  • Also in the liver, we found large L3 of up to about 10mm in length together with juveniles and mature adults from February to March.
  • In spite of their length, large L3 have 4 rows of hooklets, and their gonads remained undeveloped.
  • Morphological features of the small and large L3 of G. turgidum are described including scanning electron microscope images.
  • The seasonal switching of the several growth stages of G. turgidum from small L3 to adult worms in the liver and eventual migration to the stomach in opossums suggests the unique feature of G. turgidum utilizing the liver as the maturation site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447468.001).
  • [ISSN] 1873-0329
  • [Journal-full-title] Parasitology international
  • [ISO-abbreviation] Parasitol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Helminth; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


9. Geiger SM, Fujiwara RT, Santiago H, Corrêa-Oliveira R, Bethony JM: Early stage-specific immune responses in primary experimental human hookworm infection. Microbes Infect; 2008 Nov-Dec;10(14-15):1524-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After an initial rise in proliferative responses against larval and adult worm antigens, the cellular reactivity decreased until the end of pre-patency, rose again during patency, and dropped after chemotherapy.
  • Before infection and during the course of infection, elevated concentrations of TNF-alpha were detected in supernatants of peripheral blood mononuclear cells (PBMC) stimulated in vitro with third-stage (L3) or adult worm excretory-secretory (ES) antigens, which dropped off after chemotherapy.
  • After stimulation with L3 antigen, elevated concentrations of CCL17 were detected in supernatants during pre-patency and patency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848637.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / K01TW00009
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Chemokine CCL17; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


10. Kooyman FN, Ploeger HW, Höglund J, VAN Putten JP: Differential N-glycan- and protein-directed immune responses in Dictyocaulus viviparus-infected and vaccinated calves. Parasitology; 2007 Feb;134(Pt 2):269-79

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the search for protection-inducing antigens, we found that several D. viviparus third-stage larval (L3) and adult ES products carry N-glycans.
  • Challenge infection resulted in increased specific serum antibody levels against ES and L3 in the re-infected and challenge control groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032477.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Immunodominant Epitopes; 0 / Polysaccharides
  •  go-up   go-down


11. García-Coiradas L, Angulo-Cubillán F, Méndez S, Larraga V, de la Fuente C, Cuquerella M, Alunda JM: Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus. Parasitol Res; 2009 Jan;104(2):363-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus.
  • The putative protective antigen, p26/23, from adult Haemonchus contortus was isolated.
  • A soluble extract from adult helminths obtained from the abomasa of hyperinfected (12,000 infective larvae) female Manchego lambs and treated with a mixture of protease inhibitors was subjected to affinity chromatography (hexylgluthatione) to eliminate the enzyme gluthatione S-transferase.
  • This allowed the isolation of a single protein, which was expressed in both infective larvae (L3) and the adult stage of the parasite.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825413.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth
  •  go-up   go-down


12. Huber A, Prosl H, Joachim A, Simpson HV, Pedley KC: Effects of excretory/secretory products of Haemonchus contortus on cell vacuolation. Parasitol Res; 2005 Jul;96(5):290-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used the latter approach to examine, at the cellular level, the effects of ES prepared from L3 and adult nematodes.
  • Both NR uptake and cellular vacuolation were increased following exposure to larval or adult ES products.
  • ES preparations from adult worms induced more extensive vacuolation then those from L3 worms and, as with VacA treatment, adherent cells remained viable despite high levels of vacuolation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918071.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Helminth Proteins
  •  go-up   go-down


13. McVeigh P, Leech S, Marks NJ, Geary TG, Maule AG: Gene expression and pharmacology of nematode NLP-12 neuropeptides. Int J Parasitol; 2006 May 31;36(6):633-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcription was also identified in both L3 and adult stages of T. colubriformis, in which Tc-nlp-12 is expressed in a single tail neurone.
  • Conversely, As-nlp-12 is expressed in both head and tail tissue of adult female A. suum, suggesting species-specific differences in the transcription pattern of this gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600246.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY347872/ DQ186899
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; 0 / Neuropeptides; 0 / aspartyl-tyrosyl-arginyl-prolyl-leucyl-glutaminyl-phenylalaninamide
  •  go-up   go-down


14. Dávila C, Malagón D, Valero A, Benítez R, Adroher FJ: Anisakis simplex: CO(2)-fixing enzymes and development throughout the in vitro cultivation from third larval stage to adult. Exp Parasitol; 2006 Sep;114(1):10-5
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anisakis simplex: CO(2)-fixing enzymes and development throughout the in vitro cultivation from third larval stage to adult.
  • The results showed that a high pCO(2), at a suitable temperature, is vital for the optimum development of these nematodes, at least from the third larval stage (L3) to adult.
  • Throughout the development of the worms studied, PEPCK activity was much higher than that of PEPC (e.g., 305 vs. 6.8 nmol/min.mg protein, respectively, in L3 collected from the host fish).
  • The activity of these enzymes in the worms cultivated in air + 5% CO(2) was highest during M3, and was also generally higher than that of those cultivated in air only, especially during molting from L3 to L4 (e.g., in recently molted L4, PEPCK activity was 3.7 times greater than that of PEPC 2.9 times greater than when cultivated in air).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600219.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide; EC 4.1.1.31 / Phosphoenolpyruvate Carboxylase; EC 4.1.1.49 / Phosphoenolpyruvate Carboxykinase (ATP)
  •  go-up   go-down


15. Bricarello PA, Zaros LG, Coutinho LL, Rocha RA, Silva MB, Kooyman FN, De Vries E, Yatsuda AP, Amarante AF: Immunological responses and cytokine gene expression analysis to Cooperia punctata infections in resistant and susceptible Nelore cattle. Vet Parasitol; 2008 Aug 1;155(1-2):95-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum IgG1 mean levels against C. punctata antigens were higher in the resistant group, but significant differences between groups were only observed 14 days after the beginning of the experiment against infective larvae (L3) and 14 and 84 days against adult antigens.
  • The resistant group also presented higher IgA levels against C. punctata (L3 and adult) antigens with significant difference 14 days after the beginning of the trial (P<0.05).
  • In the small-intestine mucosa, levels of IgA anti-L3 and anti-adult C. punctata were higher in the resistant group, compared with the susceptible group (P<0.05).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513872.001).
  • [ISSN] 0304-4017
  • [Journal-full-title] Veterinary parasitology
  • [ISO-abbreviation] Vet. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulin A
  •  go-up   go-down


16. Don TA, Oksov Y, Lustigman S, Loukas A: Saposin-like proteins from the intestine of the blood-feeding hookworm, Ancylostoma caninum. Parasitology; 2007 Mar;134(Pt 3):427-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both Ac-slp-1 and slp-2 mRNAs were shown to be expressed in all life stages assessed, with slp-1 predominantly being expressed in third-stage larvae (L3) before and after activation with dog serum.
  • These antisera were used as probes in fluorescence microscopy to localize the anatomic expression sites of both proteins to small, punctate organelles or vesicles within the intestinal cells of adult worms; weak staining was detected on the microvillar brush border of the intestine.
  • Using transmission electron microscopy, both proteins were localized to similar vesicles in the intestinal cells of the L3.
  • Their expression in the gut of the L3 and adult stages suggests a role for these hookworm SAPLIPs in the lysis of host cells during tissue migration and/or feeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109779.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Helminth Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Saposins
  •  go-up   go-down


17. Dixon H, Johnston CE, Else KJ: Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection. Parasite Immunol; 2008 Sep;30(9):454-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection.
  • Subcutaneous vaccination with adult excretory-secretory products (ES) protects susceptible mouse strains from T. muris.
  • Larval stages may contain novel and more relevant antigens which when incorporated in a vaccine induce worm expulsion earlier in infection than the adult worm products.
  • This study finds negligible difference in the cellular and humoral immune response to T. muris adult and third stage larva(e) (L3) ES during a primary T. muris infection, but identifies high molecular weight proteins in both adult and L3 ES as potential vaccine candidates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565148.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 068028
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth; 0 / Cytokines; 0 / Immunoglobulin G; 0 / Vaccines
  •  go-up   go-down


18. Wang Z, Abubucker S, Martin J, Wilson RK, Hawdon J, Mitreva M: Characterizing Ancylostoma caninum transcriptome and exploring nematode parasitic adaptation. BMC Genomics; 2010;11:307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The generated transcripts from four developmental stages, infective L3, serum stimulated L3, adult male and adult female, covered 93% of the A. caninum transcriptome.
  • Examining the developmental expression profiles of A. caninum revealed major transitions in gene expression from larval stages to adult.
  • Adult males expressed the highest number of selectively expressed genes, but adult female expressed the highest number of selective parasitism-related genes.
  • Parasitism related genes were expressed more selectively in adult male and female worms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2009;533:153-87 [19277558.001]
  • [Cites] BMC Genomics. 2009;10:22 [19144180.001]
  • [Cites] Nat Genet. 1999 Jul;22(3):231-8 [10391209.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1259-67 [15543149.001]
  • [Cites] BMC Bioinformatics. 2004 Nov 30;5:187 [15571632.001]
  • [Cites] BMC Genomics. 2005;6:58 [15854223.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):961-7 [16428741.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1521-32 [16679166.001]
  • [Cites] BMC Bioinformatics. 2007;8:41 [17284313.001]
  • [Cites] Science. 2007 Sep 21;317(5845):1756-60 [17885136.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):282-8 [18171264.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Parasitol Today. 1999 May;15(5):188-93 [10322352.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):452-6 [10581034.001]
  • [Cites] Int J Parasitol. 2000 Apr 10;30(4):347-55 [10731559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3029-33 [11248026.001]
  • [Cites] Bioinformatics. 2001 Sep;17(9):847-8 [11590104.001]
  • [Cites] Mol Biochem Parasitol. 2002 Mar;120(1):1-21 [11849701.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):349-62 [11915948.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Mol Biol. 2004 May 14;338(5):1027-36 [15111065.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] J Parasitol. 1968 Jun;54(3):426-9 [5761146.001]
  • [Cites] Theor Popul Biol. 1975 Apr;7(2):256-76 [1145509.001]
  • [Cites] Annu Rev Physiol. 1981;43:323-41 [7011187.001]
  • [Cites] Mol Biol Evol. 1986 Sep;3(5):418-26 [3444411.001]
  • [Cites] J Parasitol. 1991 Aug;77(4):587-91 [1713962.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Pediatr Res. 1996 Oct;40(4):515-21 [8888276.001]
  • [Cites] Nature. 1997 May 29;387(6632):489-93 [9168109.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):129-37 [9224638.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):71-5 [9510248.001]
  • [Cites] Genome Res. 1998 Jun;8(6):590-8 [9647634.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2012-8 [9851916.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2041-6 [9851921.001]
  • [Cites] Bioinformatics. 1998;14(9):755-63 [9918945.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Mol Biochem Parasitol. 2008 Feb;157(2):187-92 [18082904.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(10):e326 [18958170.001]
  • [Cites] Nat Rev Drug Discov. 2008 Nov;7(11):900-7 [18927591.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D571-8 [18940860.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):289-97 [19042974.001]
  • [Cites] BMC Evol Biol. 2009;9:23 [19175938.001]
  • [Cites] BMC Genomics. 2009;10:114 [19296854.001]
  • (PMID = 20470405.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vaccines
  • [Other-IDs] NLM/ PMC2882930
  •  go-up   go-down


19. Glasheen JJ, Sorensen MD: Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation. Leuk Lymphoma; 2005 Feb;46(2):281-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma presenting with lactic acidosis and hypoglycemia - a case presentation.
  • We present what appears to be the first reported case of lactic acidosis and hypoglycemia in an adult patient with Burkitt's lymphoma.
  • Two prior cases of Burkitt's lymphoma-induced lactic acidosis have been reported (one child, one adult), both in the absence of hypoglycemia.
  • Thoracentesis and bone marrow studies revealed Burkitt's lymphoma.
  • [MeSH-major] Acidosis, Lactic / etiology. Burkitt Lymphoma / complications. Hypoglycemia / etiology


20. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and epidemiological features of Burkitt's lymphoma].
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • Murphy) was diagnosed in 5 patients, stage II--in 9, stage III--in 25, IV--in 14 patients, B-cell acute lymphoblastic leukemia (ALL) (L3)--in 19 patients.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


21. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


22. Nisbet AJ, Bell NE, McNeilly TN, Knox DP, Maizels RM, Meikle LI, Wildblood LA, Matthews JB: A macrophage migration inhibitory factor-like tautomerase from Teladorsagia circumcincta (Nematoda: Strongylida). Parasite Immunol; 2010 Jul;32(7):503-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cDNA representing Tci-mif-1 was isolated following its identification in third-stage larvae (L3)-enriched cDNA population.
  • Messenger RNA (mRNA) representing the Tci-MIF-1 transcript was detected in eggs, L3 and adult stages of T. circumcincta.
  • Using immunohistochemistry, the Tci-MIF-1 protein was shown to have a diffuse distribution in L3 tissue, and in L4 and adult stages, the protein was localized to the nematode gut.
  • A recombinant version of Tci-MIF-1 was produced, and enzymic assays indicated that this recombinant protein and a somatic extract of L3 possessed dopachrome tautomerase activity as has been observed previously in other MIF-like molecules.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591121.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


23. Mary KA, Hoti SL, Paily KP: Monoclonal antibodies generated against excretory/secretory antigens of mammalian stage larvae of the lymphatic filarial parasite Wuchereria bancrofti. J Immunoassay Immunochem; 2007;28(4):343-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five Mabs were obtained and, among them, Mab A7 showed high reactivity against e/s antigens of L4 and crude somatic antigens of microfilariae (mf) of W. bancrofti, and infective stage (L3) and adult stage larvae of Brugia malayi.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885888.001).
  • [ISSN] 1532-1819
  • [Journal-full-title] Journal of immunoassay & immunochemistry
  • [ISO-abbreviation] J Immunoassay Immunochem
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antibodies, Monoclonal; 0 / Antigens, Helminth
  •  go-up   go-down


24. Iwata F, Shinjyo N, Amino H, Sakamoto K, Islam MK, Tsuji N, Kita K: Change of subunit composition of mitochondrial complex II (succinate-ubiquinone reductase/quinol-fumarate reductase) in Ascaris suum during the migration in the experimental host. Parasitol Int; 2008 Mar;57(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The flavoprotein (Fp) and small subunit of cytochrome b (CybS) in adult complex II differ from those of infective third stage larval (L3) complex II.
  • However, there is no difference in the iron-sulfur cluster (Ip) or the large subunit of cytochrome b (CybL) between adult and L3 isoforms of complex II.
  • In the present study, to clarify the changes that occur in the respiratory chain of A. suum larvae during their migration in the host, we examined enzymatic activity, quinone content and complex II subunit composition in mitochondria of lung stage L3 (LL3) A. suum larvae.
  • LL3 mitochondria showed higher QFR activity ( approximately 160 nmol/min/mg) than mitochondria of A. suum at other stages (L3: approximately 80 nmol/min/mg; adult: approximately 70 nmol/min/mg).
  • Interestingly, the results of two-dimensional bule-native/sodium dodecyl sulfate polyacrylamide gel electrophoresis analyses showed that LL3 mitochondria contained larval Fp (Fp(L)) and adult Fp (Fp(A)) at a ratio of 1:0.56, and that most LL3 CybS subunits were of the adult form (CybS(A)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933581.001).
  • [ISSN] 1383-5769
  • [Journal-full-title] Parasitology international
  • [ISO-abbreviation] Parasitol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Protein Subunits; 0 / Quinones; EC 1.- / Oxidoreductases; EC 1.3.5.1 / Electron Transport Complex II; EC 1.3.99.- / quinol fumarate reductase
  •  go-up   go-down


25. Kiss JE, Gao X, Krepp JM, Hawdon JM: Interaction of hookworm 14-3-3 with the forkhead transcription factor DAF-16 requires intact Akt phosphorylation sites. Parasit Vectors; 2009 Apr 24;2(1):21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Third-stage infective larvae (L3) of hookworms are in an obligatory state of developmental arrest that ends upon entering the definitive host, where they receive a signal that re-activates development.
  • Insulin-like signaling (ILS) mediates recovery from arrest in C. elegans and activation of hookworm dauer L3.
  • RESULTS: To determine if hookworm 14-3-3 proteins play a similar role in L3 activation, hookworm FTT-2 was identified and tested for its ability to interact with A. caninum DAF-16 in vitro.
  • Ac-FTT-2 was undetectable by Western blot in excretory/secretory products from serum-stimulated (activated) L3 or adult A. caninum.
  • CONCLUSION: The results indicate that Ac-FTT-2 interacts with DAF-16 in a phosphorylation-site dependent manner, and suggests that Ac-FTT-2 mediates activation of L3 by binding Ac-DAF-16 during hookworm infection.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2007 Jun 6;25(23):4533-9 [17485147.001]
  • [Cites] Dev Biol. 2007 Jan 1;301(1):82-91 [17098225.001]
  • [Cites] Int J Parasitol. 2005 Dec;35(14):1489-98 [16135366.001]
  • [Cites] Int J Parasitol. 2005 Mar;35(3):303-13 [15722082.001]
  • [Cites] Mech Ageing Dev. 2006 Sep;127(9):741-7 [16860373.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] Parasitology. 2006 Apr;132(Pt 4):535-43 [16388693.001]
  • [Cites] Sci STKE. 2005 Aug 9;2005(296):re10 [16091624.001]
  • [Cites] Adv Parasitol. 1963;1:109-77 [14117619.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1438-52 [10364160.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):887-93 [9885576.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2488-98 [9716402.001]
  • [Cites] Science. 1997 Aug 15;277(5328):942-6 [9252323.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):994-9 [9353126.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1319-22 [9360933.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):536-9 [8700226.001]
  • [Cites] Curr Opin Genet Dev. 1996 Oct;6(5):618-23 [8939719.001]
  • [Cites] Mol Biochem Parasitol. 1996 Sep;80(1):113-7 [8885227.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Exp Parasitol. 1995 Mar;80(2):205-11 [7895832.001]
  • [Cites] Mol Biochem Parasitol. 1995 Jan;69(1):127-30 [7723782.001]
  • [Cites] Genetics. 1994 May;137(1):107-20 [8056303.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1277-83 [3203906.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5692 [3387244.001]
  • [Cites] J Parasitol. 1990 Jun;76(3):394-8 [2112598.001]
  • [Cites] Dev Biol. 1975 Oct;46(2):326-42 [1183723.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D423-6 [14681448.001]
  • [Cites] Protein Eng Des Sel. 2004 Jun;17(6):527-36 [15314210.001]
  • [Cites] Brief Bioinform. 2004 Jun;5(2):150-63 [15260895.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):3392-9 [15247332.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):329-42 [15167810.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] Nitric Oxide. 2004 May;10(3):150-5 [15158694.001]
  • [Cites] Int J Parasitol. 2004 Jun;34(7):873-80 [15157770.001]
  • [Cites] Biochemistry. 2003 Dec 30;42(51):15264-72 [14690436.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):575-81 [14642768.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36323-7 [12865427.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Int J Parasitol. 2003 Jul 30;33(8):787-93 [12865078.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Vaccine. 2003 Jan 17;21(5-6):431-9 [12531641.001]
  • [Cites] Am J Trop Med Hyg. 2002 Mar;66(3):238-44 [12139214.001]
  • [Cites] Int J Parasitol. 2002 Jun;32(6):685-93 [12062487.001]
  • [Cites] Mol Biochem Parasitol. 2002 May;121(2):205-11 [12034454.001]
  • [Cites] J Parasitol. 2001 Aug;87(4):733-8 [11534634.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3061-4 [11709560.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13402-10 [11124266.001]
  • [Cites] Parasite Immunol. 2001 Apr;23(4):213-7 [11298298.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3534-46 [11313479.001]
  • [Cites] FEBS Lett. 2001 Feb 9;490(1-2):65-9 [11172812.001]
  • [Cites] Parasite Immunol. 2000 Oct;22(10):521-8 [11012978.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):27-33 [10637628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):460-5 [10618440.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Int J Parasitol. 2009 Mar;39(4):407-15 [18930062.001]
  • [Cites] Biotechnol Adv. 2009 Mar-Apr;27(2):122-32 [18977428.001]
  • [Cites] Exp Parasitol. 2008 Aug;119(4):447-52 [18410929.001]
  • [Cites] Exp Parasitol. 2008 Aug;119(4):516-23 [18316081.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] Vaccine. 2007 Oct 10;25(41):7217-23 [17707955.001]
  • (PMID = 19393088.001).
  • [ISSN] 1756-3305
  • [Journal-full-title] Parasites & vectors
  • [ISO-abbreviation] Parasit Vectors
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI069293; United States / NIAID NIH HHS / AI / R01 AI069293-03; United States / NIAID NIH HHS / AI / R01 AI069293-01A1; United States / NIAID NIH HHS / AI / AI069293-02; United States / NIAID NIH HHS / AI / R21 AI062857; United States / NIAID NIH HHS / AI / AI069293-01A1; United States / NIAID NIH HHS / AI / AI069293-03; United States / NIAID NIH HHS / AI / R01 AI069293-02
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683825
  •  go-up   go-down


26. Rastogi MV, Desai N, Quintos JB: Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. J Pediatr Endocrinol Metab; 2008 Aug;21(8):805-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma.
  • Lactic acidosis is likewise an uncommon complication of hematological malignancy associated mainly with leukemia and lymphoma.
  • Most cases of NICTH and lactic acidosis have been described in the adult population.
  • We report a child with congenital HIV and AIDS who developed Burkitt's lymphoma, lactic acidosis and NICTH.
  • PATIENT: An 11 year-old boy with AIDS, cerebral palsy and seizure disorder presented with intractable hypoglycemia 12 days after diagnosis of Burkitt's lymphoma.
  • [MeSH-major] Acidosis, Lactic / complications. Acidosis, Lactic / diagnosis. Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Hypoglycemia / complications. Hypoglycemia / diagnosis


27. Brand AM, Varghese G, Majewski W, Hawdon JM: Identification of a DAF-7 ortholog from the hookworm Ancylostoma caninum. Int J Parasitol; 2005 Dec;35(14):1489-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infective hookworm L3 encounter a host specific signal during invasion that re-activates suspended developmental pathways.
  • In the free-living nematode Caenorhabditis elegans, recovery from the developmentally arrested dauer stage in response to environmental cues is analogous to the resumption of development in invading hookworm L3.
  • An insulin-like signalling pathway mediates L3 activation in hookworms.
  • Sequence from a hookworm expressed sequence tag was used to design specific primers for PCR amplification of Ac-daf-7 from Ancylostoma caninum infective L3 cDNA.
  • Ac-daf-7 mRNA was strongly detected by reverse transcriptase PCR in L3 and serum stimulated L3 cDNA, and weakly in cDNA from L1 and adult life cycle stages.
  • Antiserum against Escherichia coli expressed recombinant Ac-DAF-7 detected the mature protein in L3 and adult soluble extracts, but not in excretory/secretory products from serum stimulated L3 or adults.
  • Increased expression in arrested L3 stages suggests that Ac-daf-7 is important for developmental arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135366.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ058687/ DQ059758
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Caenorhabditis elegans Proteins; 0 / DAF-7 protein, C elegans; 0 / Transforming Growth Factor beta
  •  go-up   go-down


28. Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J: Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica; 2005 Jul;90(7):990-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
  • Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs lymphoma/leukemia (BL) in adults.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Leukemia / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Aged. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use


29. Delaney A, Williamson A, Brand A, Ashcom J, Varghese G, Goud GN, Hawdon JM: Cloning and characterisation of an aspartyl protease inhibitor (API-1) from Ancylostoma hookworms. Int J Parasitol; 2005 Mar;35(3):303-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using sequence from the hookworm expressed sequence tag project, specific primers were designed and used to amplify Ac-api-1 from A. caninum infective L3 cDNA by PCR.
  • The A. ceylanicum api-1 cDNA of 878 bp was cloned from L3 cDNA using the A. caninum primers.
  • Ac-api-1 mRNA was detected by reverse transcriptase PCR in eggs, L1, L3 and adult life cycle stages.
  • A polyclonal antiserum against Escherichia coli expressed recombinant Ac-API-1 detected the protein in adult A. caninum excretory/secretory products, but not in those from activated infective larvae.
  • Immunolocalisation experiments using the antiserum indicated that Ac-API-1 is present primarily in the pseudocoelomic fluid in adult hookworms.
  • Soluble, yeast-expressed Ac-API-1 failed to inhibit pepsin or a hookworm gut aspartyl protease in vitro, but inhibited approximately 30% of the proteolytic activity of adult excretory/secretory products.
  • The pseudocoleomic location, presence in all life cycle stages, lack of inhibitory activity against pepsin, and inhibitory activity against excretory/secretory products suggest that Ac-API-1 inhibits an unidentified, putative aspartyl protease secreted by adult hookworms, and may be released as an enzyme-inhibitor complex.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722082.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY705928/ AY705929
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases
  •  go-up   go-down


30. Wang WM, Guan YG, Liu F, Wang TH, Xu XY, Ke Q, Lu YC, Yuan Y: [The influence of partial dorsal root rhizotomy on IGF-I expression in spared root ganglion and spinal cord]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jan;36(1):31-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the temporospatial changes of IGF-I expression in the spared dorsal root ganglia (DRG, L6) on the operated side and un-operated side, in the spinal lamina II (L3, L5, L6) and Clarke's nucleus (L3) of the adult cats that have undergone partial dorsal rhizotomy, and compare them against those of the normal adult cats so as to unveil the relation between IGF-I and the plasticity of spinal cord.
  • METHODS: Fifteen male adult cats were divided into three groups.
  • The bilateral L6 dorsal root ganglia and L3, L5, L6 spinal cord of all groups were made into frozen sections 20 microm thick.
  • The distribution and the number of IGF-I positive neurons in bilateral spared DRG (L6) on the operated/un-operated side, in spinal lamina I (L3, L5, L6) and in Clarke' nucleus (L3) of each animal were observed and counted.
  • On the 14th day, the IGF-I expression in neurons of L6 DRG on the operated side was significantly lower than that of normal group and that of L6 spared DRG on the unoperated side (P<0.01), but it was not significantly different from that of the 7th day group (P>0.05). (2) There was no difference in number of IGF-I positive neuron in L3, L5, L6 spinal lamina II between normal group, 7th day post-operation group and 14th day post-operation group (P>0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702774.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


31. Attias D, Weitzman S: The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr; 2008 Feb;20(1):17-22
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
  • PURPOSE OF REVIEW: This review evaluates whether rituximab has efficacy in high-grade pediatric B-cell lymphoma/leukemia.
  • Current pediatric protocols for CD20+ B-cell lymphoma/leukemia significantly improve survival, but with major morbidity.
  • To assess whether rituximab has efficacy in very high-grade pediatric disease, all published data on rituximab therapy for Burkitt's lymphoma/B acute lymphoblastic leukaemia (B-ALL) and pediatric patients with relapsed/refractory large B-cell lymphoma were reviewed.
  • RECENT FINDINGS: Three trials in adult Burkitt's/B-ALL showed a significant survival advantage when rituximab was added to standard chemotherapy.
  • SUMMARY: Rituximab has demonstrated efficacy in Burkitt's disease in adults.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Child. Humans. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197034.001).
  • [ISSN] 1040-8703
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 53
  •  go-up   go-down


32. Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):726-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
  • The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).
  • Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas.
  • The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Gene Expression Regulation. Gene Expression Regulation, Leukemic. Hematopoietic Stem Cells / metabolism. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Humans. Middle Aged. Phenotype. Phosphorylation. Receptors, Antigen, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467082.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


33. Jarrett RF: Viruses and lymphoma/leukaemia. J Pathol; 2006 Jan;208(2):176-86
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human T-cell leukaemia virus type 1 causes adult T-cell leukaemia and the Epstein-Barr virus is associated with Burkitt's lymphoma, lymphomas in immunosuppressed people, and Hodgkin lymphoma.
  • [MeSH-major] Leukemia / virology. Lymphoma / virology
  • [MeSH-minor] Adult. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. HIV / immunology. Hepacivirus / immunology. Herpesvirus 1, Cercopithecine / immunology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / immunology. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Hodgkin Disease / virology. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / immunology. Humans. Simian virus 40 / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2006 Jul;209(3):420-1; author reply 422-4 [16639695.001]
  • (PMID = 16362996.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


34. Zekri AR, Mohamed W, Bahnassy A, Refat L, Khaled M, Shalaby S, Hafez M: Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies. Leuk Lymphoma; 2007 Sep;48(9):1828-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SV40 DNA sequences were found in (53.8%) of NHL, (29.6%) of HD and in (40.7%) of different types of leukemia cases.
  • The highest frequency was in Burkitt's lymphoma followed by diffuse large B-cell lymphoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786720.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


35. Brenner B, Hoffman R, Balashov D, Shutluko E, Culić SD, Nizamoutdinova E: Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost; 2005 Oct;11(4):401-10
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, B-cell or T-cell lymphoma, or aplastic anemia received rFVIIa at total doses of between 18 and 1040 mug/kg body weight.
  • [MeSH-major] Factor VIIa / therapeutic use. Hemorrhage / drug therapy. Hemorrhage / etiology. Leukemia / complications. Lymphoma / complications. Thrombocytopenia / complications
  • [MeSH-minor] Adolescent. Adult. Anticoagulants / therapeutic use. Child. Child, Preschool. Female. Humans. Internet. Male. Medical Audit. Middle Aged. Prothrombin / metabolism. Thromboplastin / metabolism

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244765.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 9001-26-7 / Prothrombin; 9035-58-9 / Thromboplastin; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


36. Berrington de González A, Urban MI, Sitas F, Blackburn N, Hale M, Patel M, Ruff P, Sur R, Newton R, Beral V: Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer; 2006;1:2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, Epstein-Barr Virus is considered a cause of Burkitt's lymphoma and other immunosuppression related lymphomas, Hodgkin lymphoma, and nasopharyngeal cancer.
  • METHODS: We conducted a systematic sub-study from within an ongoing case control study of adult black South Africans to investigate the relationship between antibodies to six human herpesviruses and seven cancer groups that may be caused by infectious agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1996 Mar 1;65(5):584-90 [8598307.001]
  • [Cites] J Med Virol. 1994 Mar;42(3):224-7 [7911825.001]
  • [Cites] Ann Epidemiol. 1995 Nov;5(6):497-500 [8680614.001]
  • [Cites] Eur J Cancer Prev. 1998 Jun;7(3):201-6 [9696928.001]
  • [Cites] J Infect Dis. 1998 Sep;178(3):846-9 [9728556.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1103-6 [10362124.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1863-71 [10369849.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] Epidemiol Rev. 2001;23(1):144-51 [11588840.001]
  • [Cites] Leukemia. 2002 Apr;16(4):716-9 [11960354.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1604-13 [12419786.001]
  • [Cites] J Exp Pathol. 1992;6(1-2):95-105 [1320669.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1229-31 [1331626.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):753-5 [15728806.001]
  • [Cites] Microbiol Immunol. 1991;35(11):1023-7 [1663574.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):829-33 [2159435.001]
  • [Cites] Eur J Cancer. 1995;31A(9):1479-86 [7577076.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • (PMID = 17150131.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1635002
  •  go-up   go-down


37. Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma; 2006 Aug;47(8):1511-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients achieving a complete remission had Burkitt's lymphoma.
  • The activity in Burkitt's lymphoma should be investigated further.
  • [MeSH-minor] Adult. Aged. Burkitt Lymphoma / drug therapy. Disease-Free Survival. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / therapeutic use. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Topoisomerase I Inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966261.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin
  •  go-up   go-down


38. Gökbuget N, Hoelzer D: Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2006;19(4):701-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antibody-based therapy for acute lymphoblastic leukaemia.
  • In recent decades rapid improvements in the results of treatment of adult acute lymphoblastic leukaemia (ALL) have been achieved.
  • However, results in adult patients are still considerably inferior to those in paediatric ALL, and a barrier to further intensification of chemotherapy appears to have been reached regarding toxicity.
  • In ALL, rituximab is combined with chemotherapy mainly in mature B-ALL and Burkitt's lymphoma, and interim results are very promising.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997178.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD
  • [Number-of-references] 54
  •  go-up   go-down


39. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).
  • METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Infant. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430665.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens
  •  go-up   go-down


40. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


41. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


42. Wolk M, Martin JE, Reinus C: Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues. J Clin Pathol; 2006 Jun;59(6):598-602
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunoaffinity-purified anti-HbF was immunohistochemically used to study F cell distribution in the following cancers: colorectal adenocarcinoma, urinary bladder transitional cell carcinoma, brain tumours, lung carcinoma, breast adenocarcinoma, leukaemia, Burkitt's lymphoma and endometrial carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Breast Neoplasms / blood supply. Erythroblasts / metabolism. Female. Humans. Leukemia / blood. Lung Neoplasms / blood supply. Male. Middle Aged. Urinary Bladder Neoplasms / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blut. 1990 Jul;61(1):17-20 [1696840.001]
  • [Cites] Tumour Biol. 1991;12(1):45-51 [1705048.001]
  • [Cites] Blood. 1995 Jul 1;86(1):323-8 [7795240.001]
  • [Cites] Pediatr Res. 1995 Oct;38(4):555-63 [8559609.001]
  • [Cites] Blood. 1996 Jan 15;87(2):557-66 [8555477.001]
  • [Cites] Immunol Today. 1998 May;19(5):228-36 [9613041.001]
  • [Cites] Semin Hematol. 2004 Oct;41(4 Suppl 6):3-10 [15534851.001]
  • [Cites] Development. 1999 Nov;126(22):5073-84 [10529424.001]
  • [Cites] Blood. 2000 May 1;95(9):2967-74 [10779447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1847-52 [11172039.001]
  • [Cites] Haematologica. 2002 Mar;87(3):323-5 [11869947.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1478-83 [12145688.001]
  • [Cites] Ann Hematol. 2002 Sep;81(9):548-50 [12373361.001]
  • [Cites] Blood. 2003 Jan 15;101(2):492-7 [12393703.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1669-76 [12406884.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1929-33 [14592835.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):740-5 [15220368.001]
  • [Cites] Ann N Y Acad Sci. 1974 Nov 29;241(0):638-52 [4611309.001]
  • [Cites] Acta Haematol. 1977;58(5):288-93 [74180.001]
  • [Cites] J Pathol. 1981 May;134(1):71-80 [6169819.001]
  • (PMID = 16469830.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9034-63-3 / Fetal Hemoglobin
  • [Other-IDs] NLM/ PMC1860403
  •  go-up   go-down


43. Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E: Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol; 2005 Mar;205(4):507-13
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ZAP-70 is a tyrosine kinase that participates in early B-cell differentiation and is a prognostic factor in chronic lymphocytic leukaemia (CLL), where it is associated with an unmutated configuration of the IgV(H) genes.
  • ZAP-70 was positive in 34/52 (65%) CLL, 9/31 (31%) Burkitt's lymphoma, 2/7 (29%) lymphoblastic lymphomas, 3/36 (8%) MCL, 1/23 (4%) marginal zone lymphoma, and 1/45 (2%) diffuse large B-cell lymphomas, but in none of the 19 follicular lymphomas or the 14 Hodgkin lymphomas.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, B-Cell / chemistry. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry / methods. Genes, Immunoglobulin / genetics. Hodgkin Disease / genetics. Hodgkin Disease / metabolism. Humans. Immunohistochemistry / methods. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / metabolism. Male. Middle Aged. Mutation. Prognosis. ZAP-70 Protein-Tyrosine Kinase

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


44. Valmary S, Danjoux M, Delsol G, Brousset P: [Diagnostic value of anti-terminal deoxynucleotidyl transferase antibody (TdT) in hematologic pathology]. Ann Pathol; 2005 Feb;25(1):25-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction between immature (lymphoblastic lymphoma/acute lymphoblastic leukaemia) and mature lymphoma is sometimes difficult.
  • MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic lymphomas, 2 Burkitt's lymphomas, 5 B and T acute lymphoblastic leukemias and 2 acute monoblastic leukemias.
  • TdT is not expressed by mature B or T cell lymphomas such as Burkitt's lymphomas.
  • Significant numbers of cases of acute myeloblastic leukemias are TdT positive but could be easily distinguished from lymphoblastic proliferations.
  • CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating lymphoma/acute lymphoblastic leukemia from other lymphomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Burkitt Lymphoma / diagnosis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukemia, Monocytic, Acute / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981929.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


45. Leone G, Sica S, Voso MT, Rutella S, Pagano L: Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects. Cardiovasc Hematol Agents Med Chem; 2006 Jan;4(1):33-52
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects.
  • In ALL, rituximab, a humanized anti CD20 antibody, has been combined to chemotherapy mainly in mature B-ALL and Burkitt's lymphoma and preliminary results are promising.
  • Alemtuzumab is an anti-CD52 humanized antibody, which showed anti-tumour activity in CLL; clinical effects were observed in some patients with relapsed adult ALL.
  • Monoclonal antibodies against myeloid antigens have been prevalently used in acute myeloid leukaemias (AML), where the most utilised immunological target is CD33.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Cell Proliferation / drug effects. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529548.001).
  • [ISSN] 1871-5257
  • [Journal-full-title] Cardiovascular & hematological agents in medicinal chemistry
  • [ISO-abbreviation] Cardiovasc Hematol Agents Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 166
  •  go-up   go-down


46. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM: Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant; 2009 May;15(5):547-53
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses included diffuse large B-cell lymphoma (n = 18), Burkitt's lymphoma (n = 3), transformed B cell lymphoma (n = 5), mantle cell lymphoma (n = 11), and peripheral T cell lymphoma (n = 9).
  • The rate of grade II-IV acute graft-versus-host disease (aGVHD) was 43%.
  • [MeSH-minor] Adult. Disease Progression. Follow-Up Studies. Graft vs Host Disease. Humans. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1893-8 [18949613.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Eur J Haematol. 2008 Dec;81(6):425-31 [18774954.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):202-8 [11328303.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):141-8 [11902564.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Cancer. 1979 Aug;44(2):645-51 [383259.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1989 Nov 15;74(7):2579-84 [2804380.001]
  • [Cites] N Engl J Med. 1995 Apr 20;332(16):1045-51 [7898521.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4085-9 [8943841.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):893-9 [9613781.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):645-50 [9818691.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):154-61 [10520036.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):205-13 [15937505.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Blood. 2006 Jul 1;108(1):382-9 [16522821.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • (PMID = 19361746.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS561999; NLM/ PMC3953134
  •  go-up   go-down


47. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ: Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med; 2005 Apr 18;201(8):1229-41
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular lymphomas, diffuse large B cell lymphomas, Burkitt's lymphomas, and myelomas expressed a CDR3 repertoire comparable to that of normal B cells.
  • Mantle cell lymphomas and B cell chronic lymphocytic leukemias (B-CLLs) expressed clearly restricted albeit different CDR3 repertoires.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Complementarity Determining Regions. Female. Humans. Immunoglobulin Heavy Chains / chemistry. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Light Chains / chemistry. Immunoglobulin Light Chains / genetics. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Amino Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1996 Jul;10(7):1190-7 [8684001.001]
  • [Cites] Eur J Immunol. 1996 Oct;26(10):2480-6 [8898963.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4445-51 [8977236.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):919-27 [9060830.001]
  • [Cites] Blood. 1997 May 1;89(9):3335-44 [9129040.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):830-6 [9217184.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1307-15 [9351568.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):804-10 [9504941.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3003-9 [12842981.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] J Clin Invest. 2004 Apr;113(7):1008-16 [15057307.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1864-72 [9490668.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):277-87 [9520941.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4292-9 [9596678.001]
  • [Cites] Immunol Rev. 1998 Apr;162:261-80 [9602370.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] Dev Immunol. 1998;6(3-4):187-95 [9814592.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1092-7 [10344290.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;246:217-22; discussion 223-4 [10396059.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Clin Immunol. 1999 Nov;93(2):132-42 [10527689.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):766-76 [3136072.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] J Exp Med. 1989 Jan 1;169(1):255-68 [2462608.001]
  • [Cites] J Autoimmun. 1988 Oct;1(5):469-81 [2473761.001]
  • [Cites] Exp Cell Res. 1989 Aug;183(2):463-72 [2767160.001]
  • [Cites] Int J Hematol. 1999 Oct;70(3):200-6 [10561915.001]
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1393-9 [10666216.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Blood. 2000 May 1;95(9):2922-9 [10779440.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3878-84 [10845923.001]
  • [Cites] Eur J Immunol. 2000 Oct;30(10):2918-23 [11069074.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19012-9 [11262391.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1884-5 [11398794.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2259-61 [11877309.001]
  • [Cites] Nature. 2002 Apr 11;416(6881):603-7 [11948342.001]
  • [Cites] Leukemia. 2002 Apr;16(4):636-44 [11960344.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1286-94 [11984515.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1349-56 [12133958.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2199-202 [12481138.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1113-22 [12651604.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2067-71 [12727821.001]
  • [Cites] Blood. 2003 May 15;101(10):4047-54 [12637326.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4500-4 [12560217.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):519-25 [15314077.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2499-504 [15217828.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2879-85 [15217826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jun;78(6):3799-803 [6167990.001]
  • [Cites] J Immunol Methods. 1984 May 11;70(1):83-90 [6201562.001]
  • [Cites] Science. 1987 May 29;236(4805):1103-6 [2883731.001]
  • [Cites] Blood. 1990 Aug 1;76(3):562-9 [2378986.001]
  • [Cites] J Clin Invest. 1990 Oct;86(4):1320-8 [2170450.001]
  • [Cites] J Am Acad Dermatol. 1991 Apr;24(4):584-90 [2033136.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] J Exp Med. 1992 Apr 1;175(4):983-91 [1552291.001]
  • [Cites] Cell Immunol. 1992 Sep;143(2):310-23 [1324802.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):285-92 [8424461.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3103-12 [7693035.001]
  • [Cites] Arthritis Rheum. 1994 Jun;37(6):860-8 [8003058.001]
  • [Cites] Immunol Today. 1995 May;16(5):237-42 [7779254.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3630-7 [7561062.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3528-34 [7579460.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] J Pathol. 1996 Feb;178(2):122-7 [8683376.001]
  • (PMID = 15837810.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY281324/ AY281325/ AY281326/ AY281327/ AY281328/ AY281329/ AY281330/ AY281331/ AY281332/ AY281333/ AY281334/ AY281335/ AY281336/ AY281337/ AY281338/ AY281339/ AY281340/ AY281341/ AY281342/ AY281343/ AY466502/ AY466503/ AY561708/ AY927657/ AY927658/ AY927659/ AY927660/ AY927661/ AY927662/ AY927663/ AY927664/ AY927665/ AY927666/ AY927667/ AY927668
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 9009-79-4 / Rheumatoid Factor
  • [Other-IDs] NLM/ PMC2213160
  •  go-up   go-down


48. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, Ruminy P, Picquenot JM, Tilly H: Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia; 2007 Mar;21(3):515-23
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal translocations joining the immunoglobulin (IG) and MYC genes have been extensively reported in Burkitt's and non-Burkitt's lymphomas but data concerning MYC rearrangements with non-IG partners are scarce.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Cell-Specific Activator Protein / genetics. Base Sequence. Burkitt Lymphoma / genetics. Carrier Proteins / genetics. Cell Transformation, Neoplastic / genetics. Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 2 / ultrastructure. Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 3 / ultrastructure. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 7 / ultrastructure. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / ultrastructure. DNA-Binding Proteins / genetics. Female. Humans. Ikaros Transcription Factor / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Molecular Sequence Data. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230227.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BCL11A protein, human; 0 / BCL6 protein, human; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / IKZF1 protein, human; 0 / Nuclear Proteins; 0 / PAX5 protein, human; 148971-36-2 / Ikaros Transcription Factor
  •  go-up   go-down


49. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]
  • [Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]
  • [Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]
  • [Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]
  • [Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]
  • [Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]
  • [Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]
  • [Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]
  • [Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]
  • (PMID = 18577266.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2438337
  •  go-up   go-down


50. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Gujral S, Shet TM, Kane SV: Morphological spectrum of AIDS-related plasmablastic lymphomas. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We classified PBL into three morphological subtypes (immunoblastic - 25, Burkitt's - 7, plasmacytic - 2).
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417882.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


52. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy; 2006 Feb;26(2):242-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor lysis syndrome is a life-threatening complication of chemotherapy for patients with leukemia and large tumors with a high proliferative index, such as Burkitt's lymphoma.
  • The drug is approved by the United States Food and Drug Administration for management of elevated plasma uric acid levels in pediatric patients with leukemia, lymphoma, or solid tumor malignancies who are receiving chemotherapy.
  • We undertook a retrospective review of adult patients treated with a single dose of rasburicase 6 mg for hyperuricemia associated with malignancy.
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Creatinine / blood. Female. Humans. Leukemia / complications. Lymphoma / complications. Male. Middle Aged. Retrospective Studies. Uric Acid / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466328.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; AYI8EX34EU / Creatinine; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


53. de Larrinoa AF, del Cura J, Zabala R, Fuertes E, Bilbao F, Lopez JI: Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. J Clin Ultrasound; 2007 Jul-Aug;35(6):295-301
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SBCL (39), LBCL (36), HD (15), T cell lymphomas (5), and miscellaneous (7) [including T cell-rich B cell (2), natural killer cell (1), Burkitt's lymphoma (1), and non-Hodgkin's lymphoma of the B cell type, NOS (3)] were correctly diagnosed.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Hodgkin Disease / diagnosis. Humans. Killer Cells, Natural / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17486566.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Moran H, Yaniv I, Ashkenazi S, Schwartz M, Fisher S, Levy I: Risk factors for typhlitis in pediatric patients with cancer. J Pediatr Hematol Oncol; 2009 Sep;31(9):630-4
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence was highest in patients with Burkitt's lymphoma (15%) and acute myeloblastic leukemia (12%).
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bacteremia / complications. Bacteremia / epidemiology. Case-Control Studies. Child. Child, Preschool. Combined Modality Therapy. Diagnostic Imaging. Female. Hematopoietic Stem Cell Transplantation. Humans. Immunocompromised Host. Incidence. Infant. Israel / epidemiology. Length of Stay / statistics & numerical data. Male. Mucositis / chemically induced. Mucositis / epidemiology. Neutropenia / complications. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Postoperative Complications / therapy. Recurrence. Retrospective Studies. Risk Factors. Single-Blind Method. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644402.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


55. Engels EA: Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):401-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphocyte-transforming viruses include Epstein Barr virus (linked to Burkitt's lymphoma, NHLs in immunosuppressed individuals, and extranodal natural killer/T-cell NHL), human herpesvirus 8 (primary effusion lymphoma), and human T lymphotropic virus type I (adult T-cell leukemia/lymphoma).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337646.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


56. Tanabe Y, Muraoka A, Ryu T, Saito T: [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus]. Nihon Naika Gakkai Zasshi; 2008 Jan 10;97(1):150-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus].
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ileus / etiology. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283903.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


57. Raina V, Medhi K, Kataria S, Kumar R, Chopra A, Kalita D, Kadam PA: Burkitt's leukemia after treatment of primary mediastinal nonseminomatous germ cell tumor. J Clin Oncol; 2008 May 1;26(13):2212-4
Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's leukemia after treatment of primary mediastinal nonseminomatous germ cell tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / pathology. Carcinoma, Embryonal / therapy. Mediastinal Neoplasms / therapy. Teratoma / therapy
  • [MeSH-minor] Adult. Fatal Outcome. Gene Expression Regulation, Neoplastic. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Billio A, Svaldi M, Morello E, Amato B, Coser P: A case of relapsed meningeal Burkitt's leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine. Am J Hematol; 2006 Oct;81(10):798-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of relapsed meningeal Burkitt's leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Cytarabine / administration & dosage
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Dose-Response Relationship, Drug. Follow-Up Studies. Humans. Injections, Intraventricular. Male. Recurrence. Remission Induction. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838326.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement